VitaSpring Biomedical Co. Ltd.
VSBC · OTC
1/31/2023 | 1/31/2022 | 1/31/2021 | 1/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $5,613 | $248 | $15 |
| % Growth | -100% | 2,161.6% | 1,539.4% | – |
| Cost of Goods Sold | $219 | $3,545 | $136 | $13 |
| Gross Profit | -$219 | $2,068 | $112 | $2 |
| % Margin | – | 36.8% | 45.2% | 11.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $569 | $536 | $21 |
| SG&A Expenses | $626 | $569 | $536 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3,333 | $16 | $1 | $0 |
| Operating Expenses | $3,959 | $585 | $537 | $21 |
| Operating Income | -$4,178 | $1,481 | -$425 | -$19 |
| % Margin | – | 26.4% | -171.4% | -128.7% |
| Other Income/Exp. Net | $8 | -$2 | -$1 | $0 |
| Pre-Tax Income | -$4,170 | $1,481 | -$425 | $7 |
| Tax Expense | -$5 | $217 | $0 | $0 |
| Net Income | -$4,164 | $1,264 | -$425 | $7 |
| % Margin | – | 22.5% | -171.4% | 45.7% |
| EPS | -0.02 | 0.006 | -0.005 | 0 |
| % Growth | -431.1% | 229.8% | -1,275% | – |
| EPS Diluted | -0.02 | 0.006 | -0.005 | 0 |
| Weighted Avg Shares Out | 206,521 | 205,984 | 91,090 | 54,510 |
| Weighted Avg Shares Out Dil | 206,521 | 205,984 | 91,090 | 54,510 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $2 | $1 | $0 |
| Depreciation & Amortization | $219 | $8 | $0 | $0 |
| EBITDA | -$3,950 | $1,492 | -$424 | -$19 |
| % Margin | – | 26.6% | -170.9% | -125.7% |